Matinas BioPharma Holdings, a development-stage biopharmaceutical company, has acquired all of the outstanding stock of Aquarius BioTechnologies, an innovative bio-delivery drug discovery company with a novel and proprietary lipid-crystal nano-particle cochleate
formulation technology platform, it was reported yesterday.
Aquarius' lipid-crystal nano-particle cochleate
formulation was developed in collaboration with Rutgers, The State University of New Jersey, which has granted Aquarius exclusive worldwide licenses under applicable patents.
has announced that results of animal studies show that the patented cochleate
based delivery system Bioral(TM), used with aspirin, improves efficacy at significantly lower dosage and substantially reduces gastrointestinal side effects.
BDSI is also working with its patented Bioral cochleate
technology to facilitate oral dosing of drugs that would otherwise require intravenous administration.